Bod Science Past Earnings Performance

Past criteria checks 0/6

Bod Science's earnings have been declining at an average annual rate of -4.2%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 20.2% per year.

Key information

-4.2%

Earnings growth rate

14.6%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate20.2%
Return on equityn/a
Net Margin-239.5%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Here's Why We're Watching Bod Australia's (ASX:BDA) Cash Burn Situation

Sep 23
Here's Why We're Watching Bod Australia's (ASX:BDA) Cash Burn Situation

Bod Australia (ASX:BDA) Is In A Good Position To Deliver On Growth Plans

Jun 07
Bod Australia (ASX:BDA) Is In A Good Position To Deliver On Growth Plans

Why Bod Australia's (ASX:BDA) CEO Pay Matters

Feb 22
Why Bod Australia's (ASX:BDA) CEO Pay Matters

Revenue & Expenses Breakdown

How Bod Science makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:BOD Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 233-843
31 Mar 234-743
31 Dec 224-642
30 Sep 225-652
30 Jun 225-552
31 Mar 226-552
31 Dec 218-552
30 Sep 218-552
30 Jun 217-452
31 Mar 217-442
31 Dec 207-542
30 Sep 207-542
30 Jun 206-532
31 Mar 204-642
31 Dec 192-641
30 Sep 192-752
30 Jun 191-852
31 Mar 191-642
31 Dec 181-532
30 Sep 181-431
30 Jun 181-421
31 Mar 181-321
31 Dec 171-320
30 Sep 171-320
30 Jun 170-320
31 Mar 170-320
31 Dec 160-210
30 Sep 160-110
30 Jun 160000
30 Jun 150000

Quality Earnings: BOD is currently unprofitable.

Growing Profit Margin: BOD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BOD is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.

Accelerating Growth: Unable to compare BOD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BOD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).


Return on Equity

High ROE: BOD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies